Fate Therapeutics/$FATE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Fate Therapeutics
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Ticker
$FATE
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
181
ISIN
US31189P1021
Website
FATE Metrics
BasicAdvanced
$139M
-
-$1.49
2.32
-
Price and volume
Market cap
$139M
Beta
2.32
52-week high
$5.92
52-week low
$0.66
Average daily volume
2M
Financial strength
Current ratio
8.815
Quick ratio
8.695
Long term debt to equity
26.624
Total debt to equity
28.893
Profitability
EBITDA (TTM)
-168.277
Gross margin (TTM)
-766.36%
Net profit margin (TTM)
-1,318.93%
Operating margin (TTM)
-1,392.96%
Revenue per employee (TTM)
$70,000
Management effectiveness
Return on assets (TTM)
-23.97%
Return on equity (TTM)
-49.23%
Valuation
Price to revenue (TTM)
10.707
Price to book
0.48
Price to tangible book (TTM)
0.48
Price to free cash flow (TTM)
-1.141
Free cash flow yield (TTM)
-87.67%
Free cash flow per share (TTM)
-106.08%
Growth
Revenue change (TTM)
105.85%
Earnings per share change (TTM)
-22.33%
3-year revenue growth (CAGR)
-40.44%
3-year earnings per share growth (CAGR)
-15.13%
10-year earnings per share growth (CAGR)
1.33%
What the Analysts think about FATE
Analyst ratings (Buy, Hold, Sell) for Fate Therapeutics stock.
FATE Financial Performance
Revenues and expenses
FATE Earnings Performance
Company profitability
FATE News
AllArticlesVideos
Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress
GlobeNewsWire·1 week ago
Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors
GlobeNewsWire·3 weeks ago
Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Fate Therapeutics stock?
Fate Therapeutics (FATE) has a market cap of $139M as of June 20, 2025.
What is the P/E ratio for Fate Therapeutics stock?
The price to earnings (P/E) ratio for Fate Therapeutics (FATE) stock is 0 as of June 20, 2025.
Does Fate Therapeutics stock pay dividends?
No, Fate Therapeutics (FATE) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Fate Therapeutics dividend payment date?
Fate Therapeutics (FATE) stock does not pay dividends to its shareholders.
What is the beta indicator for Fate Therapeutics?
Fate Therapeutics (FATE) has a beta rating of 2.32. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.